SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K, Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan GE, Macinnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner R, Li L, Marrie T, Sykes BD, Vogel HJ, Querengesser L. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007; 35: D5216.
  • 2
    Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008; 455: 10546.
  • 3
    Nicholson JK, Wilson ID. High resolution proton magnetic resonance spectroscopy of biological fluids. Prog Nucl Magn Reson Spectrosc 1989; 21: 449501.
  • 4
    Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHZ 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 1995; 67: 793811.
  • 5
    Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007; 2: 2692703.
  • 6
    Beckonert O, Coen M, Keun HC, Wang Y, Ebbels TM, Holmes E, Lindon JC, Nicholson JK. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc 2010; 5: 101932.
  • 7
    Bruce SJ, Tavazzi I, Parisod V, Rezzi S, Kochhar S, Guy PA. Investigation of human blood plasma sample preparation for performing metabolomics using ultrahigh performance liquid chromatography/mass spectrometry. Anal Chem 2009; 81: 328596.
  • 8
    Wilson ID, Plumb R, Granger J, Major H, Williams R, Lenz EM. HPLC-MS-based methods for the study of metabonomics. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 817: 6776.
  • 9
    Ejsing CS, Sampaio JL, Surendranath V, Duchoslav E, Ekroos K, Klemm RW, Simons K, Shevchenko A. Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry. Proc Natl Acad Sci U S A 2009; 106: 213641.
  • 10
    Pietilainen KH, Sysi-Aho M, Rissanen A, Seppanen-Laakso T, Yki-Jarvinen H, Kaprio J, Oresic M. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects – a monozygotic twin study. PLoS ONE 2007; 2: e218.
  • 11
    Martin FP, Montoliu I, Kochhar S, Rezzi S. Chemometric strategy for modeling metabolic biological space along the gastrointestinal tract and assessing microbial influences. Anal Chem 2010; 82: 980311.
  • 12
    Richards SE, Dumas ME, Fonville JM, Ebbels TMD, Holmes E, Nicholson JK. Intra- and inter-omic fusion of metabolic profiling data in a systems biology framework. Chemometr Intelligent Lab Syst 2010; 104: 12131.
  • 13
    Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007; 6: 46979.
  • 14
    Solanky KS, Bailey NJ, Beckwith-Hall BM, Davis A, Bingham S, Holmes E, Nicholson JK, Cassidy A. Application of biofluid 1H nuclear magnetic resonance-based metabonomic techniques for the analysis of the biochemical effects of dietary isoflavones on human plasma profile. Anal Biochem 2003; 323: 197204.
  • 15
    Rezzi S, Ramadan Z, Martin FP, Fay LB, van Bladeren P, Lindon JC, Nicholson JK, Kochhar S. Human metabolic phenotypes link directly to specific dietary preferences in healthy individuals. J Proteome Res 2007; 6: 446977.
  • 16
    Stella C, Beckwith-Hall B, Cloarec O, Holmes E, Lindon JC, Powell J, van der OF, Bingham S, Cross AJ, Nicholson JK. Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res 2006; 5: 27808.
  • 17
    Rezzi S, Martin FP, Shanmuganayagam D, Colman RJ, Nicholson JK, Weindruch R. Metabolic shifts due to long-term caloric restriction revealed in nonhuman primates. Exp Gerontol 2009; 44: 35662.
  • 18
    Heinzmann SS, Brown IJ, Chan Q, Bictash M, Dumas ME, Kochhar S, Stamler J, Holmes E, Elliott P, Nicholson JK. Metabolic profiling strategy for discovery of nutritional biomarkers: proline betaine as a marker of citrus consumption. Am J Clin Nutr 2010; 92: 43643.
  • 19
    Martin FP, Sprenger N, Yap IK, Wang Y, Bibiloni R, Rochat F, Rezzi S, Cherbut C, Kochhar S, Lindon JC, Holmes E, Nicholson JK. Panorganismal gut microbiome-host metabolic crosstalk. J Proteome Res 2009; 8: 2090105.
  • 20
    Claus SP, Ellero SL, Berger B, Krause L, Bruttin A, Molina J, Paris A, Want EJ, de Waziers I, Cloarec O, Richards SE, Wang Y, Dumas ME, Ross A, Rezzi S, Kochhar S, van Bladeren P, Lindon JC, Holmes E, Nicholson JK. Colonization-induced host-gut microbial metabolic interaction. MBio 2011; 2: e0027110.
  • 21
    Merrifield CA, Lewis M, Claus SP, Beckonert OP, Dumas ME, Duncker S, Kochhar S, Rezzi S, Lindon JC, Bailey M, Holmes E, Nicholson JK. A metabolic system-wide characterisation of the pig: a model for human physiology. Mol Biosyst 2011; 7: 257788.
  • 22
    Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 2009; 106: 3698703.
  • 23
    Martin FP, Wang Y, Yap IK, Sprenger N, Lindon JC, Rezzi S, Kochhar S, Holmes E, Nicholson JK. Topographical variation in murine intestinal metabolic profiles in relation to microbiome speciation and functional ecological activity. J Proteome Res 2009; 8: 346474.
  • 24
    Martin FP, Dumas ME, Wang Y, Legido-Quigley C, Yap IK, Tang H, Zirah S, Murphy GM, Cloarec O, Lindon JC, Sprenger N, Fay LB, Kochhar S, van Bladeren P, Holmes E, Nicholson JK. A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol 2007; 3: 11227.
  • 25
    Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 2005; 3: 4318.
  • 26
    Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 2002; 22: 283307.
  • 27
    Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 5129.
  • 28
    Madden JA, Hunter JO. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 2002; 88 (Suppl. 1): S6772.
  • 29
    Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease. Curr Gastroenterol Rep 2003; 5: 51823.
  • 30
    Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001; 120: 62235.
  • 31
    Lin HM, Helsby NA, Rowan DD, Ferguson LR. Using metabolomic analysis to understand inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 10219.
  • 32
    Winterkamp S, Weidenhiller M, Otte P, Stolper J, Schwab D, Hahn EG, Raithel M. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 30717.
    Direct Link:
  • 33
    Bjerrum JT, Nielsen OH, Hao F, Tang H, Nicholson JK, Wang Y, Olsen J. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res 2010; 9: 95462.
  • 34
    Le GG, Noor SO, Ridgway K, Scovell L, Jamieson C, Johnson IT, Colquhoun IJ, Kemsley EK, Narbad A. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res 2011; 10: 420818.
  • 35
    Martin FP, Rezzi S, Philippe D, Tornier L, Messlik A, Holzlwimmer G, Baur P, Quintanilla-Fend L, Loh G, Blaut M, Blum S, Kochhar S, Haller D. Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice. J Proteome Res 2009; 8: 237687.
  • 36
    Murdoch TB, Fu H, Macfarlane S, Sydora BC, Fedorak RN, Slupsky CM. Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. Anal Chem 2008; 80: 552431.
  • 37
    Williams HR, Cox IJ, Walker DG, North BV, Patel VM, Marshall SE, Jewell DP, Ghosh S, Thomas HJ, Teare JP, Jakobovits S, Zeki S, Welsh KI, Taylor-Robinson SD, Orchard TR. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol 2009; 104: 143544.
  • 38
    Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P, Shanahan F, Wilson ID, Wang Y. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007; 6: 54651.
  • 39
    Jansson J, Willing B, Lucio M, Fekete A, Dicksved J, Halfvarson J, Tysk C, Schmitt-Kopplin P. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS ONE 2009; 4: e6386.
  • 40
    Schicho R, Nazyrova A, Shaykhutdinov R, Duggan G, Vogel HJ, Storr M. Quantitative metabolomic profiling of serum and urine in DSS-induced ulcerative colitis of mice by (1)H NMR spectroscopy. J Proteome Res 2010; 9: 626573.
  • 41
    Otter D, Cao M, Lin HM, Fraser K, Edmunds S, Lane G, Rowan D. Identification of urinary biomarkers of colon inflammation in IL10−/− mice using Short-Column LCMS metabolomics. J Biomed Biotechnol 2011; 974701713.
  • 42
    Lin HM, Barnett MP, Roy NC, Joyce NI, Zhu S, Armstrong K, Helsby NA, Ferguson LR, Rowan DD. Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn's disease. J Proteome Res 2010; 9: 196575.
  • 43
    Sharma U, Singh RR, Ahuja V, Jagannathan NR, Makharia GK. Similarity in the metabolic profile in macroscopically involved and un-involved colonic mucosa in patients with inflammatory bowel disease: an in vitro proton ((1)H) MR spectroscopy study. Magn Reson Imaging 2010; 28: 10229.
  • 44
    Balasubramanian K, Kumar S, Singh RR, Sharma U, Ahuja V, Makharia GK, Jagannathan NR. Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study. Magn Reson Imaging 2009; 27: 7986.
  • 45
    Baur P, Martin FP, Gruber L, Bosco N, Brahmbhatt V, Collino S, Guy P, Montoliu I, Rozman J, Klingenspor M, Tavazzi I, Thorimbert A, Rezzi S, Kochhar S, Benyacoub J, Kollias G, Haller D. Metabolic phenotyping of the Crohn's disease-like IBD etiopathology in the TNF(DeltaARE/WT) Mouse Model. J Proteome Res 2011; 552335.
  • 46
    Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 150417.
  • 47
    Barbara G, De GR, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002; 51 (Suppl. 1): i414.
  • 48
    Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318: 5656.
  • 49
    Martin FP, Verdu EF, Wang Y, Dumas ME, Yap IK, Cloarec O, Bergonzelli GE, Corthesy-Theulaz I, Kochhar S, Holmes E, Lindon JC, Collins SM, Nicholson JK. Transgenomic metabolic interactions in a mouse disease model: interactions of trichinella spiralis infection with dietary lactobacillus paracasei supplementation. J Proteome Res 2006; 5: 218593.
  • 50
    Rezzi S, Martin FP, Alonso C, Guilarte M, Vicario M, Ramos L, Martinez C, Lobo B, Saperas E, Malagelada JR, Santos J, Kochhar S. Metabotyping of biofluids reveals stress-based differences in gut permeability in healthy individuals. J Proteome Res 2009; 8: 4799809.
  • 51
    Bertini I, Calabro A, De Carli V, Luchinat C, Nepi S, Porfirio B, Renzi D, Saccenti E, Tenori L. The metabonomic signature of celiac disease. J Proteome Res 2009; 8: 1707.
  • 52
    Tjellstrom B, Stenhammar L, Hogberg L, Falth-Magnusson K, Magnusson KE, Midtvedt T, Sundqvist T, Norin E. Gut microflora associated characteristics in children with celiac disease. Am J Gastroenterol 2005; 100: 27848.
    Direct Link:
  • 53
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Fernando C. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive Summary. Crit Pathw Cardiol 2005; 4: 198203.
  • 54
    Wirfalt E, Hedblad B, Gullberg B, Mattisson I, Andren C, Rosander U, Janzon L, Berglund G. Food patterns and components of the metabolic syndrome in men and women: a cross-sectional study within the Malmo Diet and Cancer cohort. Am J Epidemiol 2001; 154: 11509.
  • 55
    Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9: 31126.
  • 56
    Suhre K, Meisinger C, Doring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM, Mewes HW, Hrabe de AM, Wichmann HE, Kronenberg F, Adamski J, Illig T. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 2010; 5: e13953.
  • 57
    Huffman KM, Shah SH, Stevens RD, Bain JR, Muehlbauer M, Slentz CA, Tanner CJ, Kuchibhatla M, Houmard JA, Newgard CB, Kraus WE. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 2009; 32: 167883.
  • 58
    Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS ONE 2010; 5: e15234.
  • 59
    Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, Yang E, Farrell L, Fox CS, O'Donnell CJ, Carr SA, Vasan RS, Florez JC, Clish CB, Wang TJ, Gerszten RE. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 2011; 121: 140211.
  • 60
    Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med 2011; 17: 44853.
  • 61
    Huffman KM, Slentz CA, Bateman LA, Thompson D, Muehlbauer MJ, Bain JR, Stevens RD, Wenner BR, Kraus VB, Newgard CB, Kraus WE. Exercise-induced changes in metabolic intermediates, hormones, and inflammatory markers associated with improvements in insulin sensitivity. Diabetes Care 2011; 34: 1746.
  • 62
    Lanza IR, Zhang S, Ward LE, Karakelides H, Raftery D, Nair KS. Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS ONE 2010; 5: e10538.
  • 63
    Sysi-Aho M, Ermolov A, Gopalacharyulu PV, Tripathi A, Seppanen-Laakso T, Maukonen J, Mattila I, Ruohonen ST, Vahatalo L, Yetukuri L, Harkonen T, Lindfors E, Nikkila J, Ilonen J, Simell O, Saarela M, Knip M, Kaski S, Savontaus E, Oresic M. Metabolic regulation in progression to autoimmune diabetes. PLoS Comput Biol 2011; 7: e1002257.
  • 64
    Nikkila J, Sysi-Aho M, Ermolov A, Seppanen-Laakso T, Simell O, Kaski S, Oresic M. Gender-dependent progression of systemic metabolic states in early childhood. Mol Syst Biol 2008; 4: 197.
  • 65
    Oresic M, Simell S, Sysi-Aho M, Nanto-Salonen K, Seppanen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lahde J, Suortti T, Hakalax J, Simell T, Hyoty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008; 205: 297584.
  • 66
    Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 67989.
  • 67
    Johnson NA, Walton DW, Sachinwalla T, Thompson CH, Smith K, Ruell PA, Stannard SR, George J. Noninvasive assessment of hepatic lipid composition: advancing understanding and management of fatty liver disorders. Hepatology 2008; 47: 151323.
  • 68
    Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010; 5: 14571.
  • 69
    James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495501.
  • 70
    Day CP, James OF. Steatohepatitis: a tale of two ‘hits’? Gastroenterology 1998; 114: 8425.
  • 71
    Rull A, Vinaixa M, Angel RM, Beltran R, Brezmes J, Canellas N, Correig X, Joven J. Metabolic phenotyping of genetically modified mice: an NMR metabonomic approach. Biochimie 2009; 91: 10537.
  • 72
    Li H, Wang L, Yan X, Liu Q, Yu C, Wei H, Li Y, Zhang X, He F, Jiang Y. A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. J Proteome Res 2011; 10: 2797806.
  • 73
    Barr J, Vazquez-Chantada M, Alonso C, Perez-Cormenzana M, Mayo R, Galan A, Caballeria J, Martin-Duce A, Tran A, Wagner C, Luka Z, Lu SC, Castro A, Le Marchand-Brustel Y, Martinez-Chantar ML, Veyrie N, Clement K, Tordjman J, Gual P, Mato JM. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res 2010; 9: 450112.
  • 74
    Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, Milburn M. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011; 60: 40413.
  • 75
    Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, Zhang R, McIntyre TM, Hazen SL. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010; 51: 304654.
  • 76
    Tulipani S, Llorach R, Jauregui O, Lopez-Uriarte P, Garcia-Aloy M, Bullo M, Salas-Salvado J, Andres-Lacueva C. Metabolomics Unveils Urinary Changes in Subjects with Metabolic Syndrome following 12-Week Nut Consumption. J Proteome Res 2011; 10: 504758.
  • 77
    Yap IK, Brown IJ, Chan Q, Wijeyesekera A, Garcia-Perez I, Bictash M, Loo RL, Chadeau-Hyam M, Ebbels T, De IM, Maibaum E, Zhao L, Kesteloot H, Daviglus ML, Stamler J, Nicholson JK, Elliott P, Holmes E. Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study. J Proteome Res 2010; 9: 664754.
  • 78
    Makinen VP, Soininen P, Forsblom C, Parkkonen M, Ingman P, Kaski K, Groop PH, la-Korpela M. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol 2008; 4: 167.
  • 79
    Kell DB. Metabolomic biomarkers: search, discovery and validation. Expert Rev Mol Diagn 2007; 7: 32933.
  • 80
    Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 9104.
  • 81
    Sawyers CL. The cancer biomarker problem. Nature 2008; 452: 54852.
  • 82
    Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem 2007; 363: 18595.
  • 83
    Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, Konsgen D, Dietel M, Fiehn O. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006; 66: 10795804.
  • 84
    Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu QH, Chiong E, Chan EC. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res 2010; 9: 298895.
  • 85
    Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, Saruki N, Bando E, Kimura H, Imamura F, Moriyama M, Ikeda I, Chiba A, Oshita F, Imaizumi A, Yamamoto H, Miyano H, Horimoto K, Tochikubo O, Mitsushima T, Yamakado M, Okamoto N. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS ONE 2011; 6: e24143.
  • 86
    Li M, Song Y, Cho N, Chang JM, Koo HR, Yi A, Kim H, Park S, Moon WK. An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS ONE 2011; 6: e25563.
  • 87
    Gu H, Pan Z, Xi B, Asiago V, Musselman B, Raftery D. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer. Anal Chim Acta 2011; 686: 5763.
  • 88
    Moazzami AA, Zhang JX, Kamal-Eldin A, Aman P, Hallmans G, Johansson JE, Andersson SO. Nuclear magnetic resonance-based metabolomics enable detection of the effects of a whole grain rye and rye bran diet on the metabolic profile of plasma in prostate cancer patients. J Nutr 2011; 141: 212632.
  • 89
    Yap IK, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK. Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res 2010; 9: 29963004.
  • 90
    Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM, Kaddurah-Daouk R. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 2011; 6: e21643.
  • 91
    Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res 2011; 10: 543343.
  • 92
    Oresic M, Tang J, Seppanen-Laakso T, Mattila I, Saarni SE, Saarni SI, Lonnqvist J, Sysi-Aho M, Hyotylainen T, Perala J, Suvisaari J. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med 2011; 3: 19.